Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC)

Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC)

Early-stage NSCLC (stages I and II, and some IIIA diseases) accounts for approximately 30% of non-small cell lung cancer (NSCLC) cases, with surgery being its main treatment modality. The risk of disease recurrence and cancer-related death, however, remains high among NSCLC patients after complete s...

Full description

Bibliographic Details
Main Authors: Li-Chung Chiu, Shu-Min Lin, Yu-Lun Lo, Scott Chih-Hsi Kuo, Cheng-Ta Yang, Ping-Chih Hsu
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Vaccines
Subjects:
immunotherapy
programmed death-ligand 1 (PD-L1)
cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)
immune checkpoint inhibitor
non-small cell lung cancer (NSCLC)
cancer vaccination
Online Access:https://www.mdpi.com/2076-393X/9/7/689

Internet

https://www.mdpi.com/2076-393X/9/7/689

Similar Items